You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sanofi and Regeneron’s Dupixent shows positive results in phase 3 trial

A phase 3 trial assessing the investigational use of Sanofi and Regeneron’s Dupixent – also known as dupilumab – in children aged one to 11 years with eosinophilic oesophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens.